Steven H. Stein
Net Worth
Last updated:
What is Steven H. Stein net worth?
The estimated net worth of Dr. Steven H. Stein is at least $27,770,450 as of 12 Aug 2024. He owns shares worth $7,692,340 as insider, has earned $12,335,710 from insider trading and has received compensation worth at least $7,742,400 in Incyte Corporation.
What is the salary of Steven H. Stein?
Dr. Steven H. Stein salary is $967,800 per year as Executive Vice President & Chief Medical Officer in Incyte Corporation.
How old is Steven H. Stein?
Dr. Steven H. Stein is 58 years old, born in 1967.
What stocks does Steven H. Stein currently own?
As insider, Dr. Steven H. Stein owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Incyte Corporation (INCY) | Executive Vice President & Chief Medical Officer | 90,011 | $85.46 | $7,692,340 |
What does Incyte Corporation do?
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Steven H. Stein insider trading
Incyte Corporation
Dr. Steven H. Stein has made 14 insider trades between 2017-2024, according to the Form 4 filled with the SEC. Most recently he sold 11,608 units of INCY stock worth $703,793 on 12 Aug 2024.
The largest trade he's ever made was exercising 33,006 units of INCY stock on 6 Jul 2020. As of 12 Aug 2024 he still owns at least 90,011 units of INCY stock.
Incyte key executives
Incyte Corporation executives and other stock owners filed with the SEC:
- Dr. Barry P. Flannelly M.B.A., Pharm.D., MBA (67) Executive Vice President & GM of North America
- Dr. Steven H. Stein (58) Executive Vice President & Chief Medical Officer
- Dr. Vijay K. Iyengar M.D. (52) Executive Vice President of Global Strategy & Corporation Devel.
- Mr. Herve Hoppenot (65) Chairman, Pres & Chief Executive Officer
- Ms. Christiana Stamoulis (54) Executive Vice President & Chief Financial Officer